# A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events

Study · id `cardio:ct-nct07729475` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07729475](<https://clinicaltrials.gov/study/NCT07729475>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07729475

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07729475. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-27 (anticipated); primary completion 2026-12-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07729475, source copy `cardio:ctgov-nct07729475-2026-07-27`, retrieved 2026-10-31)
- Planned start: 2026-07-27 (anticipated) (ClinicalTrials.gov record NCT07729475, source copy `cardio:ctgov-nct07729475-2026-07-27`, retrieved 2026-10-31)
- Primary completion: 2026-12-12 (anticipated) (ClinicalTrials.gov record NCT07729475, source copy `cardio:ctgov-nct07729475-2026-07-27`, retrieved 2026-10-31)
- Completion: 2027-04-30 (anticipated) (ClinicalTrials.gov record NCT07729475, source copy `cardio:ctgov-nct07729475-2026-07-27`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07729475, source copy `cardio:ctgov-nct07729475-2026-07-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07729475-2026-07-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events
- Condition: Elevated Lipoprotein(a)
- Intervention (Drug): SAL0137 Dose 1
- Intervention (Drug): SAL0137 Dose 2
- Intervention (Drug): SAL0137 Dose 3
- Intervention (Drug): Placebo
- Lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. (`cardio:org-shenzhen-salubris-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 6d4dd9f43074f35dfc2120e58123d33abba9dc3fb1a348cfb13319a9474d1600
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
